| Dr Samuel Alan Antonian, PHARMD | |
|
400 W Northfield Dr, Brownsburg, IN 46112-8122 | |
| (317) 858-1415 | |
| Not Available |
| Full Name | Dr Samuel Alan Antonian |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 400 W Northfield Dr, Brownsburg, Indiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194403147 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 26030313A (Indiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Samuel Alan Antonian, PHARMD 400 W Northfield Dr, Brownsburg, IN 46112-8122 Ph: (317) 858-1415 | Dr Samuel Alan Antonian, PHARMD 400 W Northfield Dr, Brownsburg, IN 46112-8122 Ph: (317) 858-1415 |
News Archive
Simultaneously elevated levels of the biomarkers C-reactive protein, fibrinogen and leukocyte count in individuals with chronic obstructive pulmonary disease (COPD) were associated with increased risk of having exacerbations, even in those with milder COPD and in those without previous exacerbations, according to a study in the June 12 issue of JAMA.
The reported results of a one-year phase III study in 1045 people with type 2 diabetes treated with rimonabant, the first in a new class of therapeutic agents called selective CB1 Blockers, were that rimonabant 20 mg significantly improved HbA1c (a measure of blood sugar control), dyslipidemia (abnormal levels of fat in the blood), and systolic blood pressure with a concomitant substantial reduction in abdominal obesity in people with type 2 diabetes treated with oral anti-diabetic medications and requiring further control.
In the largest systematic review and meta-analysis to date on COVID-19 outcomes in individuals with psychiatric disorders, the odds of dying or being hospitalized following COVID-19 infection were determined to be twice as high in comparison to persons without mental disorders.
Boston Scientific Corporation has completed patient enrollment in the ASTI post-market clinical follow-up study designed to evaluate its Adapt Monorail Carotid Stent System in combination with its FilterWire EZ Embolic Protection System for treatment of carotid artery disease in patients at high risk for carotid surgery.
Researchers at the University of Texas Medical Branch at Galveston have identified women who are likely to gain weight while using depot medroxyprogesterone acetate, more commonly known as Depo-Provera or the birth control shot. These findings dispel the myth that all women who use DMPA will gain weight and will help physicians to counsel patients appropriately.
› Verified 5 days ago
William Markiewicz, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 905 N Green St, Brownsburg, IN 46112 Phone: 317-852-3340 Fax: 317-852-1200 | |
Mrs. Gail Celeste Levstek, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 20 W Main St, Brownsburg, IN 46112 Phone: 317-858-7834 | |
Dr. Beatrice Talai, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 21 W Main St, Brownsburg, IN 46112 Phone: 317-852-2763 | |
Glenn Eldridge, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 675 Patrick Pl, Suite F, Brownsburg, IN 46112 Phone: 765-858-6600 Fax: 800-228-0844 | |
Ms. Nickie L Huber, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 20 W Main St, Brownsburg, IN 46112 Phone: 317-858-7834 | |
Aaron Alsmeyer, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 675 Patrick Pl, Brownsburg, IN 46112 Phone: 317-858-6600 | |
Andrew Bailey, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 400 W Northfield Dr, Brownsburg, IN 46112 Phone: 317-858-1415 |